Quarterly report [Sections 13 or 15(d)]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Segment Expenses (Details)

v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Total Research and development expense $ 2,370 $ 3,492
Total Selling, general and administrative expense 2,346 2,012
Total operating expenses 4,716 5,504
Reportable Segment    
Segment Reporting Information [Line Items]    
Employee expenses 2,862 3,039
Consulting and professional fees 410 310
Clinical study expenses 143 110
Product development 112 709
Other [1] 290 304
Total Research and development expense 955 1,433
Selling, general and administrative expenses 614 735
Commercialization readiness expenses 285 297
Total Selling, general and administrative expense 899 1,032
Total operating expenses $ 4,716 $ 5,504
[1] Other primarily includes patent, software, product testing and other miscellaneous expenses for the three months ended March 31, 2026 and 2025.